Navigation Links
NuVasive to Present at Canaccord Adams Musculoskeletal Conference
Date:2/17/2009

SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Patrick Williams, Vice President, Finance, is scheduled to present at the Canaccord Adams Musculoskeletal Conference at the University of Nevada in Las Vegas, Nevada on Tuesday, February 24, 2009 at 8:20 a.m. PT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation. NuVasive's Biologic product portfolio includes FormaGraft(R), Osteocel(R) Plus, and the Progentix products, all of which are intended to facilitate fusion and complement the core fixation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Contact:                            Investors:
    Kevin C. O'Boyle                    Patrick F. Williams
    EVP & Chief Financial Officer       Vice President, Finance
    NuVasive, Inc.                      NuVasive, Inc.
    858-909-1998                        858-638-5511
    investorrelations@nuvasive.com      investorrelations@nuvasive.com

    Media:
    Jason Rando
    The Ruth Group
    646-536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
2. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
3. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
4. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
5. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
6. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
7. NuVasive Acquires First Stem Cell Bone Graft Substitute
8. NuVasive Reports First Quarter 2008 Financial Results
9. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
10. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
11. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Arizona (PRWEB) , ... December 07, 2016 , ... Delete® ... Just in Time For The Holiday Party Season. Save Up To 33% Off Botox® ... Laser Salon is providing the Phoenix Valley with Delightful Deals on Botox® ...
(Date:12/7/2016)... ... , ... The medical profession is well aware that heart attacks do indeed ... heart attacks among 138,602 people recorded a 35% higher number of heart attacks in ... of course–no time of year is a good time for a heart attack! In ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... medicine device WellnessPro Plus for consumers and healthcare professionals to manage chronic ... by expanding the treatment modalities available in a single device. The announcement ...
(Date:12/7/2016)... ... 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief but ... presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of published ... for this country. , Nancy attributes her patriotic nature to her WWII veteran father. ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... individuals impacted by cerebral cavernous angiomas, was awarded a grant from the Julian ... engagement program. New Mexico has more people with cavernous angioma than anywhere in ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Homozygous Familial Hypercholesterolemia (HoFH) - ... Global Markets Direct,s latest Pharmaceutical and Healthcare ... – Pipeline Review, H2 2016, provides an ... (Metabolic Disorders) pipeline landscape. Homozygous familial ... caused due to mutation from both parents. ...
(Date:12/6/2016)... The pen needles market is projected to reach USD ... 2016, growing at a CAGR of 11.2% during the ... years, the pen needles market has witnessed various technological ... for safety injections in the healthcare industry. These advancements ... with an aim to reduce pain, increase comfort, and ...
(Date:12/6/2016)... 2016   AlloSource , one of the ... and soft-tissue allografts for use in surgical procedures, ... for being named to the Board of Examiners ... by the Commerce Department,s National Institute of Standards ... process excellence. The Baldrige Award is the nation,s ...
Breaking Medicine Technology: